Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.
Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.
Pre diabetes (PD) is a term that refers to alterations in blood glucose levels, including
 impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, and increase in
 glycated hemoglobin (HbA1c), all this factors involving a higher risk to develop type 2
 diabetes mellitus (T2DM).

 The efficacy of pharmacotherapy in the prevention of diabetes in adults with pre diabetes has
 been demonstrated, the first line of pharmacology treatment is metformin, on the other hand,
 probiotics administration has been reported to be one of the most widely used approaches to
 modulate the gut microbiota and subsequently prevent or delay the incidence of T2DM.

 Probiotics are live microorganisms which when administered in adequate amounts confer a
 health benefit on the host. Has been demonstrated the hypoglycemic effects of the probiotics
 in different clinical trials in type 2 diabetes mellitus and pre diabetes, but no yet
 compared with metformin, for this reason comparing it´s activity against metformin in pre
 diabetes would provide impact information on a new alternative treatment compared with the
 standard pharmacological treatment.

 The aim of the study is evaluate the effect of administration of probiotic versus metformin
 on glycemic control, insulin secretion and insulin sensitivity in patients with pre diabetes.
A randomized, double-blind controlled clinical trial in 30 patients between 31 to 60 years of
 age with a diagnosis of prediabetes (IFG 100 a 125 mg/dL, IGT 140 a 199 mg/dL, HbA1c 5.7 a
 6.4%) in accordance with the American Diabetes Association without treatment.

 Patients with one or more of the following criteria will be excluded: History of liver,
 kidney or heart disease; systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90
 mmHg, HbA1c ≥6.5%, triglycerides ≥ 400 mg/dL, total cholesterol ≥240 mg/dL; pregnancy or
 lactation; consumption of medications or supplements with effects on glucose levels.

 They will be assigned randomly two groups of 15 patients; one of the groups will receive 750
 mg of metformin twice at day (before breakfast and dinner) for 13 weeks.

 The other group will receive 400 mg of probiotics 1 time at day (before breakfast) and
 placebo pill (before dinner) for 13 weeks.

 They will be measured fasting blood glucose, postprandial glucose levels and glycosylated
 hemoglobin, and will be calculated area under curve of glucose an insulin, total insulin
 secretion (Insolinogenic index), first-phase of insulin secretion (Strumvoll index) and
 insulin sensitivity (Matsuda index).

 This protocol It´s already approved by the local ethics committee and written informed
 consent it´s going to be obtained from all volunteers.

 Statistical analysis will be presented through measures of central tendency and dispersion,
 average and deviation standard for quantitative variables; frequencies and percentage for
 qualitative variable. Will be used Wilcoxon range test for identification of differences
 between baseline and final evaluation of each intervention group, Mann-Whitney U Test and
 Wilcoxon Test for the within-groups differences. It will be considered satitistical
 significance p >0.05.
Inclusion Criteria:

 -  Patients both sexes

 -  Age between 31 and 60 years

 -  Diagnosis of prediabetes according ADA criteria (fasting blood glucose levels between
 100-125 mg/dL, postprandial blood glucose levels after an oral glucose tolerance test
 with 75 g of oral glucose between 140-199 mg/dL and glycated hemoglobin between
 5.7-6.4 %)

 -  Body Mass Index from 25 to 34.9 kg/m2

 -  Stable weight at least the previous last 3 months (weight variation less than 10%)

 -  Acceptance and signing of informed consent

 Exclusion Criteria:

 -  History of kidney, liver or heart disease

 -  Women with confirmed or suspected pregnancy

 -  Women under lactation and/or puerperium

 -  Physical impossibility for taking pills

 -  Hypersensibility to ingredients of intervention

 -  Consumption of medications or supplements with effects on glucose levels

 -  Systolic blood pressure ≥ 140 mmHg

 -  Diastolic blood pressure ≥ 90 mmHg

 -  HbA1c ≥6.5%

 -  Triglycerides ≥ 400 mg/dL

 -  Total cholesterol ≥ 240 mg/dL